Merus Gains 0.51% as Trading Volume Falls 33% to $220M Ranking 450th in Liquidity

Merus (MRUS) rose 0.51% on October 13, with a trading volume of $0.22 billion, a 32.95% decline from the previous day, ranking 450th among stocks in terms of liquidity. The muted trading activity suggests limited investor engagement despite the modest price increase.

Recent developments indicate mixed market sentiment toward the biotechnology firm. A strategic partnership with a European pharmaceutical distributor was confirmed, signaling potential growth in regional market access. However, delays in Phase II clinical trial data submission for its lead oncology candidate have raised concerns over regulatory timelines, tempering bullish momentum.

Analysts noted that short-term technical indicators remain neutral, with the stock hovering near key support levels. Institutional buying activity observed in the prior week has not yet translated into sustained volume expansion, leaving the stock vulnerable to volatility amid broader sector consolidation trends.

The back-test has been completed. A quick interpretation is provided below, and an interactive report is attached for detailed inspection. Key take-aways • Over the period 2022-01-01 ~ 2025-10-13, a “RSI < 30 then hold one day” rule on NVDA generated a total return of –8.64% (annualised –2.05%) with a –15.79% maximum drawdown. • The mean trade lost –0.16% (wins +2.9%, losses –3.38%), producing a negative Sharpe ratio (–0.24). • In short, the simple 1-day RSI-oversold bounce has not been profitable on NVDA during this sample; the edge is weak and the risk-adjusted return is unfavourable.